Detalhe da pesquisa
1.
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Nature
; 600(7888): 319-323, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34819663
2.
TAS2940, a novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations.
Cancer Sci
; 114(2): 654-664, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282234
3.
TIP60 is required for tumorigenesis in non-small cell lung cancer.
Cancer Sci
; 114(6): 2400-2413, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36916958
4.
An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1.
Br J Cancer
; 128(9): 1647-1664, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36810913
5.
Long-read sequencing for non-small-cell lung cancer genomes.
Genome Res
; 30(9): 1243-1257, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32887687
6.
Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML.
Blood
; 138(15): 1331-1344, 2021 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33971010
7.
Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.
Cancer Sci
; 113(2): 597-608, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34808021
8.
Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations.
Proc Natl Acad Sci U S A
; 116(20): 10025-10030, 2019 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31043566
9.
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
Oncologist
; 26(4): 281-287, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32969527
10.
Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation.
Bioorg Med Chem Lett
; 29(16): 2286-2289, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31278031
11.
ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPα.
J Biol Chem
; 292(46): 18924-18936, 2017 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-28900037
12.
Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPα.
Molecules
; 23(8)2018 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30081475
13.
[Transcription factor-based therapies for acute myeloid leukemia].
Rinsho Ketsueki
; 59(7): 922-931, 2018.
Artigo
em Japonês
| MEDLINE | ID: mdl-30078804
14.
The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors.
JTO Clin Res Rep
; 5(1): 100614, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38229766
15.
A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice.
Cancers (Basel)
; 16(6)2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539415
16.
Metabolic Hallmarks for Purine Nucleotide Biosynthesis in Small Cell Lung Carcinoma.
Mol Cancer Res
; 22(1): 82-93, 2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37773022
17.
LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Commun Biol
; 7(1): 412, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575808
18.
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation.
J Exp Med
; 221(3)2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38284990
19.
Mathematical analysis identifies the optimal treatment strategy for epidermal growth factor receptor-mutated non-small cell lung cancer.
Front Oncol
; 13: 1137966, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37841421
20.
AXL activates YAP through the EGFR-LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma.
Oncogene
; 42(39): 2869-2877, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591955